Levallois C, Valence C, Baldet P, Privat A
INSERM U336, Ecole Nationale Supérieure de Chimie, Montpellier, France.
Brain Res Dev Brain Res. 1997 Apr 18;99(2):243-52. doi: 10.1016/s0165-3806(97)00026-6.
Primary dissociated cultures of rhombencephalon were prepared from 5-9-week-old human fetuses. Half of some cultures were treated by two non-competitive N-methyl-D-aspartate antagonists, namely 1-(2-thienyl)cyclohexylpiperidine (TCP) and cis-Pip/Mel-[1-(2-thienyl)-2-methyl-cyclohexyl]piperidine (GK11) in negative enantiomeric form, which enhance the survival of human fetal central nervous system cells in culture. At different days in vitro, the treated and the control cultures were processed for immunocytochemical detection of serotonin-containing neurons which were studied by morphological and morphometric analysis. Statistical analysis showed that the surface of the stained neurons increased as a function of two parameters of time, the gestational age of the cells and the duration of the cultures. The complexity of the shape of the serotonin neurons characterized by the shape factor, the number of bifurcations and the morphological feature (bipolar or multipolar) was found to increase with the gestational age. It appears that the in vitro development of the embryonic cells which represents stages of maturation and differentiation can be specifically evaluated. Such an analysis of fetal central nervous system cells improves the knowledge of factors important in grafting experiments. We verified that the two drugs do not appreciably alter the in vitro development of the treated cells; thus they may be considered as promising drugs for human neuroprotection.
从5至9周大的人类胎儿制备菱脑的原代解离培养物。部分培养物的一半用两种非竞争性N-甲基-D-天冬氨酸拮抗剂处理,即1-(2-噻吩基)环己基哌啶(TCP)和顺式-Pip/Mel-[1-(2-噻吩基)-2-甲基-环己基]哌啶(GK11)的阴性对映体形式,它们可提高培养的人类胎儿中枢神经系统细胞的存活率。在不同的体外培养天数,对处理过的和对照培养物进行免疫细胞化学检测含5-羟色胺的神经元,并通过形态学和形态计量学分析进行研究。统计分析表明,染色神经元的表面积随时间的两个参数、细胞的胎龄和培养持续时间而增加。发现以形状因子、分支数和形态特征(双极或多极)为特征的5-羟色胺神经元形状的复杂性随胎龄增加。似乎可以具体评估代表成熟和分化阶段的胚胎细胞的体外发育。对胎儿中枢神经系统细胞的这种分析提高了对移植实验中重要因素的认识。我们证实这两种药物不会明显改变处理过的细胞的体外发育;因此,它们可被视为有前景的人类神经保护药物。